Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
synthetic progestin |
| gptkbp:approvedInUS |
1973
|
| gptkbp:ATCCode |
G03AC01
|
| gptkbp:brand |
Aygestin
Norlutate |
| gptkbp:CASNumber |
51-98-9
|
| gptkbp:chemicalFormula |
C22H28O3
|
| gptkbp:contraindication |
gptkb:liver_disease
pregnancy thromboembolic disorders |
| gptkbp:developedBy |
norethindrone
|
| gptkbp:discoveredIn |
1950s
|
| gptkbp:eliminationHalfLife |
5–12 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
norethindrone acetate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
progestogenic activity
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache breast tenderness irregular menstrual bleeding |
| gptkbp:synonym |
gptkb:NETA
norethisterone acetate |
| gptkbp:usedFor |
contraception
hormone replacement therapy treatment of menstrual disorders treatment of endometriosis |
| gptkbp:bfsParent |
gptkb:Myfembree
|
| gptkbp:bfsLayer |
7
|